Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT323 + BNT327 in advanced breast cancer
2024-517979-20-00Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of trastuzumab pamirtecan and pumitamig in breast cancer (6 arms), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and serious adverse events and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
trastuzumab pamirtecanpumitamig
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517979-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517979-20-00.